- Home
- FAT vs CHRS Comparison
FAT vs CHRS Comparison
Compare FAT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAT
- CHRS
- Stock Information
- Founded
- FAT 2017
- CHRS 2010
- Country
- FAT United States
- CHRS United States
- Employees
- FAT N/A
- CHRS N/A
- Industry
- FAT Restaurants
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FAT Consumer Discretionary
- CHRS Health Care
- Exchange
- FAT Nasdaq
- CHRS Nasdaq
- Market Cap
- FAT 94.4M
- CHRS 100.9M
- IPO Year
- FAT 2017
- CHRS 2014
- Fundamental
- Price
- FAT $5.36
- CHRS $1.10
- Analyst Decision
- FAT
- CHRS Strong Buy
- Analyst Count
- FAT 0
- CHRS 4
- Target Price
- FAT N/A
- CHRS $6.13
- AVG Volume (30 Days)
- FAT 21.5K
- CHRS 3.3M
- Earning Date
- FAT 10-30-2024
- CHRS 11-06-2024
- Dividend Yield
- FAT 10.61%
- CHRS N/A
- EPS Growth
- FAT N/A
- CHRS N/A
- EPS
- FAT N/A
- CHRS N/A
- Revenue
- FAT $606,008,000.00
- CHRS $304,340,000.00
- Revenue This Year
- FAT $34.73
- CHRS $3.33
- Revenue Next Year
- FAT $2.67
- CHRS $16.77
- P/E Ratio
- FAT N/A
- CHRS N/A
- Revenue Growth
- FAT 42.38
- CHRS 44.19
- 52 Week Low
- FAT $4.51
- CHRS $0.66
- 52 Week High
- FAT $9.48
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- FAT 53.49
- CHRS 69.14
- Support Level
- FAT $5.10
- CHRS $0.70
- Resistance Level
- FAT $5.45
- CHRS $0.89
- Average True Range (ATR)
- FAT 0.23
- CHRS 0.11
- MACD
- FAT -0.03
- CHRS 0.05
- Stochastic Oscillator
- FAT 40.55
- CHRS 86.27
About FAT FAT Brands Inc.
FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States and the rest from other countries.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.